Literature DB >> 1686768

Selectivity of rilmenidine for the nucleus reticularis lateralis, a ventrolateral medullary structure containing imidazoline-preferring receptors.

E Tibiriça1, J Feldman, C Mermet, L Monassier, F Gonon, P Bousquet.   

Abstract

Neuronal metabolic activity was studied by in vivo electrochemistry in two brain areas of the anesthetized rat: the nucleus reticularis lateralis (NRL) region of the ventrolateral medulla oblongata - site of the hypotensive action of clonidine-like imidazolines - and the locus coeruleus (LC), which is involved in the sedative effect of these drugs. Hypotensive doses of i.v. rilmenidine (0.3 and 1.5 mg/kg), which is structurally related to clonidine, induced a dose-related inhibition of the metabolic activity of catecholaminergic neurons in the NRL region whereas higher doses (50-fold) were required to inhibit the activity of the catecholaminergic neurons in the locus coeruleus. On the other hand azepexole, another centrally acting antihypertensive drug that is not structurally related to the imidazolines failed to inhibit the neuronal metabolic activity of the NRL region when administered i.v. in hypotensive doses (1 mg/kg). Taken together, these findings suggest that the central hypotensive action of clonidine-like drugs requires the imidazoline structure or pharmacologically compatible compounds like rilmenidine. Our results also show that rilmenidine is twice as selective as clonidine for the NRL region, which contains imidazoline-preferring receptors, compared with the LC, which contains mainly alpha 2-adrenoceptors. In conclusion, this study provides a functional confirmation of the dissociation between the therapeutic (hypotensive) and untoward (sedative) effects of rilmenidine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1686768     DOI: 10.1016/0014-2999(91)90172-m

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

Review 1.  Drugs acting on imidazoline receptors: a review of their pharmacology, their use in blood pressure control and their potential interest in cardioprotection.

Authors:  P Bousquet; J Feldman
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

2.  Effects of chronic sympatho-inhibition on reflex control of renal blood flow and plasma renin activity in renovascular hypertension.

Authors:  S L Burke; R G Evans; G A Head
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

3.  No evidence for functional imidazoline receptors on locus coeruleus neurons.

Authors:  B Szabo; R Fröhlich; P Illes
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-04       Impact factor: 3.000

4.  Effects of imidazoline antihypertensive drugs on sympathetic tone and noradrenaline release in the prefrontal cortex.

Authors:  B Szabo; T Fritz; K Wedzony
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

5.  Mediation of the hypotensive action of systemic clonidine in the rat by alpha 2-adrenoceptors.

Authors:  J P Hieble; D C Kolpak
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

6.  A novel mechanism of action for hypertension control: moxonidine as a selective I1-imidazoline agonist.

Authors:  P Ernsberger; M A Haxhiu; L M Graff; L A Collins; I Dreshaj; D L Grove; M E Graves; S G Schäfer; M O Christen
Journal:  Cardiovasc Drugs Ther       Date:  1994-03       Impact factor: 3.727

7.  Sympathoinhibition by rilmenidine in conscious rabbits: involvement of alpha 2-adrenoceptors.

Authors:  B Szabo; R Urban; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-12       Impact factor: 3.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.